Published in Alzheimers Res Ther on March 08, 2013
A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimers Dement (2013) 1.15
Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurol (2015) 0.96
CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol (2014) 0.94
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimers Dement (2015) 0.90
Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimers Dement (2014) 0.89
Novel plasma biomarker surrogating cerebral amyloid deposition. Proc Jpn Acad Ser B Phys Biol Sci (2014) 0.81
Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome. Neurobiol Aging (2015) 0.80
A plasma proteolysis pathway comprising blood coagulation proteases. Oncotarget (2016) 0.77
Association between cell-bound blood amyloid-β(1-40) levels and hippocampus volume. Alzheimers Res Ther (2014) 0.76
Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. Front Neurol (2015) 0.76
Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. Front Neurol (2015) 0.76
Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma. J Alzheimers Dis (2016) 0.75
Regional Hippocampal Atrophy and Higher Levels of Plasma Amyloid-Beta Are Associated With Subjective Memory Complaints in Nondemented Elderly Subjects. J Gerontol A Biol Sci Med Sci (2016) 0.75
Measurement of creatinine in human plasma using a functional porous polymer structure sensing motif. Int J Nanomedicine (2015) 0.75
Reference Intervals for Plasma Amyloid β in Korean Adults Without Cognitive Impairment. Ann Lab Med (2016) 0.75
A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces. Sci Rep (2017) 0.75
Aβ40 has a subtle effect on Aβ42 protofibril formation, but to a lesser degree than Aβ42 concentration, in Aβ42/Aβ40 mixtures. Arch Biochem Biophys (2016) 0.75
Secretases-related miRNAs in Alzheimer's disease: new approach for biomarker discovery. Neurol Sci (2017) 0.75
Whole exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study. PLoS One (2017) 0.75
Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts. Front Aging Neurosci (2017) 0.75
Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies. Neurol Ther (2017) 0.75
Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst) (2017) 0.75
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature (1999) 5.77
Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21
Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol (2006) 4.77
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology (2006) 3.68
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25
Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci U S A (1988) 2.95
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol (2000) 2.66
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology (2003) 2.44
Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol (2003) 2.05
Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension (2012) 1.96
Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol (1999) 1.96
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement (2011) 1.85
Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A (2008) 1.84
Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol (2007) 1.81
Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology (2008) 1.71
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol (2012) 1.70
Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology (2009) 1.70
Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol (2005) 1.65
Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun (2000) 1.57
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement (2009) 1.49
Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol (2008) 1.46
Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology (2007) 1.45
Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord (2007) 1.44
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol (2011) 1.40
Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques. Proc Natl Acad Sci U S A (1990) 1.31
Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem (2004) 1.30
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement (2011) 1.30
Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology (2004) 1.23
Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett (2001) 1.21
Serum creatinine levels correlate with plasma amyloid Beta protein. Alzheimer Dis Assoc Disord (2002) 1.20
Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol (2007) 1.19
Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol (2009) 1.17
Plasma ß-amyloid and cognitive decline. Arch Neurol (2010) 1.13
Expression patterns of beta-amyloid precursor protein (beta-APP) in neural and nonneural human tissues from Alzheimer's disease and control subjects. Ann Neurol (1991) 1.12
Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry (2012) 1.12
The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology (1997) 1.10
Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging. J Alzheimers Dis (2010) 1.10
Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol (2004) 1.06
Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. Am J Geriatr Psychiatry (2010) 1.04
Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol (2008) 1.04
Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? Expert Opin Investig Drugs (2011) 1.04
Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. Alzheimers Dement (2012) 1.01
Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol (2009) 1.01
Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem (2001) 0.99
Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Mol Psychiatry (2012) 0.98
Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease. Neurobiol Aging (2011) 0.96
Change in plasma Aß peptides and onset of dementia in adults with Down syndrome. Neurology (2010) 0.96
Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis (2011) 0.94
Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome. Neurobiol Aging (2011) 0.94
Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett (1997) 0.93
Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment. Neurology (2011) 0.92
Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD. Int J Alzheimers Dis (2012) 0.92
β-amyloid dynamics in human plasma. Arch Neurol (2012) 0.91
Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm (Vienna) (2012) 0.90
Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees. Genet Epidemiol (2001) 0.90
No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int (2009) 0.90
Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. J Alzheimers Dis (2012) 0.89
Electrophoretic separation of amyloid beta peptides in plasma. Electrophoresis (2004) 0.87
Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. J Alzheimers Dis (2013) 0.86
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease. Clin Neuropharmacol (2012) 0.86
The demographic and medical correlates of plasma aβ40 and aβ42. Alzheimer Dis Assoc Disord (2013) 0.86
Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics. J Alzheimers Dis (2012) 0.83
Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients. J Alzheimers Dis (2010) 0.83
The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord (2009) 0.82
Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome. Int J Geriatr Psychiatry (2010) 0.81
Interplay between α-, β-, and γ-secretases determines biphasic amyloid-β protein level in the presence of a γ-secretase inhibitor. J Biol Chem (2012) 0.79
Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment. J Neurochem (2012) 0.79
Stability of amyloid-β peptides in plasma and serum. Electrophoresis (2012) 0.78
Linkage analysis for plasma amyloid beta levels in persons with hypertension implicates Aβ-40 levels to presenilin 2. Hum Genet (2012) 0.77